Castle Biosciences Inc (CSTL)vsIQVIA Holdings Inc (IQV)
CSTL
Castle Biosciences Inc
$32.03
+5.12%
HEALTHCARE · Cap: $928.40M
IQV
IQVIA Holdings Inc
$238.70
+2.70%
HEALTHCARE · Cap: $38.68B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 4653% more annual revenue ($16.98B vs $357.28M). IQV leads profitability with a 8.1% profit margin vs -5.4%. IQV earns a higher WallStSmart Score of 55/100 (C).
CSTL
Hold37
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.2%
Fair Value
$79.18
Current Price
$32.03
$47.15 discount
Margin of Safety
+11.9%
Fair Value
$201.09
Current Price
$238.70
$37.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 20.1% year-over-year
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Earnings declined 51.6%
Moderate valuation
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 20.1% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
CSTL profiles as a growth stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.20 — expect wider price swings.
CSTL is growing revenue faster at 20.1% — sustainability is the question.
IQV generates stronger free cash flow (491M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 37/100). CSTL offers better value entry with a 59.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Visit Website →IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?